Results of a United Kingdom real world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL

Real world study investigated polatuzumab vedotin combined with rituximab and bendamustine for treatment of relapsed diffuse large b-cell lymphoma.